St. Louis, MO - October 14, 2005 - Kereos, a biotechnology company developing targeted imaging agents and therapeutics to improve the detection and treatment of cancer and cardiovascular disease, has added a $500,000 investment from Advantage Capital Partners to its recently announced Series B Venture Financing, bringing the total raised to more than $20 million.
"We are pleased to welcome Advantage Capital to our outstanding syndicate of investors who have joined this round," said Robert A. Beardsley, Ph.D., President and CEO of Kereos. "As we advance into clinical trials in 2006, these investors stepping up now will be invaluable in developing our targeted products to tackle cancer and cardiovascular disease."
About Kereos, Inc.
Kereos develops products designed to provide more effective detection and treatment of cancer, the first two of which are expected to enter clinical trials for solid tumors in 2006. The company’s proprietary technology pairs diagnosis and therapy by targeting imaging agents or therapeutics specifically to the disease site. The company’s targeted imaging agents allow more accurate and sensitive imaging, and its targeted chemotherapeutics deliver potent and precise therapy. In addition to advancing its internal pipeline, Kereos is working with leading pharmaceutical and imaging companies, including Bristol-Myers Squibb Medical Imaging on the development and commercialization of cardiovascular disease magnetic resonance imaging (MRI) agents and Philips Medical Systems on the development of molecular imaging systems. Kereos is headquartered in St. Louis at the Center for Emerging Technologies. For more information, visit Kereos’ website at www.kereos.com.